| Page 4 | Aplastic Anemia and MDS International Foundation

Research Reveals New Treatment Approach For Acute Myeloid Leukemia

According to a story from med.miami.edu, a team of researchers working at the Sylvester Comprehensive Cancer Center, which is part of the University of Miami School of Medicine, made a significant discovery that could lead to a new approach to treating acute myeloid leukemia. Data from their research revealed than inhibiting an enzyme called CARM1 (also known as PRMT4) was able to slow down the progression of acute myeloid leukemia.

Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia

Author(s): 
Lu Y, Sun RJ, Zhao YL, Xiong M, Cao XY, Zhang JP, Wei ZJ, Zhou JR, Liu DY, Lu DP
Primary Author: 
Lu Y
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
May 2018

Salvage haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is considered in patients with severe

Bone Marrow Diseases: 

Early, Attenuated-Dose Hypomethylating Agent Therapy May Be Effective in Low-Risk MDS

Attenuated doses of hypomethylating agents (HMA) early in treatment could improve outcomes among transfusion independent patients with lower-risk myelodysplastic syndromes (MDS), according to findings that will be presented at the American Society of Clinical Oncology 2018 Annual Meeting in Chicago, Illinois.1